

BARNES & THORNBURG LLP

11 South Meridian Street
Indianapolis, Indiana 46204
(317) 236-1313

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

<i>Earliest Priority Date:</i>	03 October 2003	}
		}
		}
<i>International Serial No.:</i>	PCT/US2004/032401	}
		}
		}
<i>U.S. Serial No.:</i>	10/573,732	}
		}
		}
<i>Invention:</i>	3-SUBSTITUTED BETA-LACTAMYL VASOPRESSIN V1a ANTAGONISTS	}
		}
		}
<i>Inventors:</i>	Christopher Guillon, et al.	}
		}
		}
<i>International Filing Date:</i>	01 October 2004	}
		}
		}
<i>Attorney Docket:</i>	29010-79469	}
		}
		}
<i>Examiner:</i>	Unknown	}
		}
		}
<i>Confirmation Number:</i>	5658	}

**FILED ELECTRONICALLY
ON: MAY 1, 2007**

STATEMENT UNDER 37 C.F.R. 3.73(b)

Mail Stop: PCT
Attention: DO/EO/US
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Serenix Pharmaceutical, LLC., the original Assignee of the entire right, title, and interest in the above-captioned patent application, has merged with Azevan Pharmaceuticals, Inc., the surviving corporation. A merger document was recorded in the USPTO on January 30, 2007, at Reel 18821, frames 689-693. Accordingly, Agent for the Applicant submits herewith:


- 1) a Statement under 37 CFR 3.73(b) and
- 2) a copy of the Power of Attorney executed by Azevan Pharmaceuticals, Inc.

USSN 10/573,732
May 1, 2007
Page Two

Agent for the Applicant believes that the application is now complete, and respectfully requests that the application proceed to the Examiner.

Please charge any additional fees that may be due in connection with this submission to our Deposit Account No. 10-0435, with reference to our matter no. 29010-79469.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Kevin L. McLaren", written over a horizontal line.

Kevin L. McLaren
Attorney Registration No. 48,351

KLM/hzs/888356
Indianapolis, Indiana 46204